Cisplatin Disposition and Kidney Injury

NCT ID: NCT03817970

Last Updated: 2025-08-11

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-11-15
• Study Completion Date: 2027-12-31

Brief Summary

This study is being done to determine 1) whether drugs to treat cisplatin-related nausea can influence harm to the kidneys, 2) whether cisplatin levels in the body can influence the risk of harm to the kidneys, and 3) whether a person's genetic make-up can increase or decrease the likelihood of kidney injury due to cisplatin therapy.

Detailed Description

Cisplatin (cis-diamminedichloroplatinum, Platinol®) is commonly utilized in chemotherapy regimens for the treatment of solid cancers including lung, head and neck, and cervix. Its main mechanism of action is through binding of DNA to form cross-links, leading to arrest of DNA synthesis and replication. A major adverse consequence of cisplatin therapy is acute kidney injury (AKI). It is reported that between 30 and 38 percent of patients develop signs of nephrotoxicity (toxicity in the kidneys) after a single cisplatin dose, despite strategies such as hydration to limit renal exposure. This is problematic for patients as kidney injury can delay further treatment and limit the total number of chemotherapy cycles received, thereby reducing the overall efficacy of cisplatin-containing regimens. Furthermore, it is apparent that cisplatin will remain a central component to the treatment of solid tumors in the foreseeable future. New approaches to identify patients at risk of acute kidney injury (AKI) and prevent its development and progression are urgently needed. Cisplatin causes nausea and vomiting, which requires treatment with 5-HT3 antagonists (5-HT3A) to control. Associations between the clinical use of the 5-HT3A antiemetic drugs and the risk of cisplatin AKI have recently been discovered. This study will interrogate relationships between 5-HT3A drugs (granisetron, ondansetron, and palonosetron) and cisplatin AKI.

Conditions

Nephrotoxicity

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Granisetron

Participants randomized to an antiemetic regimen containing granisetron 2 mg oral or IV and evaluated for cisplatin toxicity after the first dose of cisplatin.

Group Type: EXPERIMENTAL

Granisetron

Intervention Type: DRUG

An antiemetic regimen containing granisetron 2 mg oral or IV.

Ondansetron

Participants randomized to an antiemetic regimen containing ondansetron 8 mg oral or IV and evaluated for cisplatin toxicity after the first dose of cisplatin.

Group Type: EXPERIMENTAL

Ondansetron

Intervention Type: DRUG

An antiemetic regimen containing ondansetron 8 mg oral or IV.

Palonosetron

Participants randomized to an antiemetic regimen containing palonosetron 0.25 mg IV and evaluated for cisplatin toxicity after the first dose of cisplatin.

Group Type: EXPERIMENTAL

Palonosetron

Intervention Type: DRUG

An antiemetic regimen containing palonosetron 0.25 mg IV.

Interventions

Granisetron

An antiemetic regimen containing granisetron 2 mg oral or IV.

Intervention Type: DRUG

Ondansetron

An antiemetic regimen containing ondansetron 8 mg oral or IV.

Intervention Type: DRUG

Palonosetron

An antiemetic regimen containing palonosetron 0.25 mg IV.

Intervention Type: DRUG

Other Intervention Names

Kytril; Zofran; Aloxi

Eligibility Criteria

Inclusion Criteria

• Male or female patient prescribed cisplatin at a dose of >25mg/m^2
• Age 18-80 years
• Hemoglobin >/=9 g/dl
• No consumption of grapefruit juice or alcohol within 7 days
• No history of alcohol consumption of >14 drinks/week
• No history of organ transplantation or kidney dialysis
• Willingness to comply with study
• Not pregnant or lactating
• No changes in chronic medications within 2 weeks
• Estimated glomerular filtration rate (eGFR) > 60 ml/min^2
• Normal liver function (ALT and AST <2x ULN)

Exclusion Criteria

• Diagnosis of kidney cancer
• Previous exposure to platinum-based chemotherapy with the exception of one previous dose as part of the current course
• Herbal supplement use beyond marijuana
• Exposure to other known nephrotoxins (including contrast agents) within the previous 2 weeks
• Severe gastrointestinal disease with fluid losses
• Diagnosis of a rapidly progressive glomerulonephritis
• Allergy or contraindication to 5-HT3 Antagonists

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Memorial Sloan Kettering Cancer Center

OTHER

Sponsor Role: collaborator

Rutgers University

OTHER

Sponsor Role: collaborator

National Institute of General Medical Sciences (NIGMS)

NIH

Sponsor Role: collaborator

University of Colorado, Denver

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Melanie Joy, PharmD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Colorado, Denver

Edgar Jaimes, MD

Role: PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Locations

UCHealth-Metro Denver

Denver, Colorado, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Countries

United States

Other Identifiers

R01GM123330

Identifier Type: NIH

Identifier Source: secondary_id

View Link

18-1752.cc

Identifier Type: -

Identifier Source: org_study_id